The study presents new terpenoid NaV1.8 inhibitors with enhanced potency, implying potential in drug development.
Herein, we present two 17(15→16)-abeo-abietane diterpenoids (1 and 2) as the first terpenoid-class NaV1.8 inhibitors, along with their first asymmetric total syntheses to enable in-depth pharmacological studies. Key steps include kinetic resolution of terminal epoxides, bioinspired polyene cyclization, and late-stage photocatalytic benzylic oxidation. Preliminary structural modifications led to 13 derivatives, among which compound 29 exhibited both a 4.3-fold improved potency compared to parent natural product 1 and preserved selectivity across other sodium-gated sodium channels.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: